The role of immunosuppression in lymphoma formation

Springer Seminars in Immunopathology

Volumn 20, Issue 3-4, 1998, Pages 343-355

  Penn, Israel ^a,b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; B LYMPHOCYTE ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACTINOMYCIN; GAMMA GLOBIN; GANCICLOVIR; INTERFERON; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INCIDENCE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; ONCOVIRINAE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIGENS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; ONCOGENIC VIRUSES;

EID: 0031739006     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002810050040     Document Type: Review

References (54)

1. 1 and its receptor by cyclosporine in human T lymphocytes. Transplantation 60: 718
2. Alfrey EJ, Friedman AL, Grossman RA, Perloff LJ, Naji A, Barker CF, Montone KT, Tomajewski JE, Chmiclewski C, Holland T, Zmijewski C, Dafoe DC (1992) Two distinct patterns of post-transplantation lymphoproliferative disorder (PTLD): early and late onset. Clin Transplant 6 : 246
3. Anderson P, Schroeder TJ, Hariharan S, First MR (1993) Incidence of post-transplant lymphoproliferative disease in OKT3-treated renal transplant recipients. Clin Transplant 7 : 582
4. Birkeland SA (1983) Cancer in transplanted patients: the Scandia-transplant material. Transplant Proc 15 : 1071
5. Burnet FM (1971) Immunological surveillance in neoplasia. Transplant Rev 7 : 3
6. Ciancio G, Siquijor AP, Burke GW, Roth D, Cirocco R, Esquenazi V, Byrne GE Jr, Miller J (1997) Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant 11 : 243
7. Darenkov, IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorher KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lorber, MI (1997) Reduced incidence of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 64 : 848
8. Demetris AJ, Nalesnik MA, Kunz HW, Gill TJ III, Shinozuka H (1984) Sequential analyses of the development of lymphoproliferative disorders in rats receiving cyclosporine. Transplantation 38: 239
9. Doody MM, Linet MS, Glass AG, Friedman GD, Pottern LM, Boice JD Jr, Fraumeni JF Jr (1992) Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 3 : 449
10. Ehrlich P (1957) Üher den jetzigen Stand der Karzinomforschung. In: The Collected Papers of Paul Ehrlich vol 2. Pergamon Press, London, p 550
11. Ellis D, Shapiro R, Jordan ML, Scantlebury VP, Gilboa N, Hopp L, Weichler N, Tzakis AG, Simmons RL (1994) Comparison of FK506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol 8: 193
12. Fukuda M, Aikawa I, Ohmori Y, Yoshimura N, Nakai L, Matui S, Oka T (1987) Chromosome aberrations in kidney transplant recipients. Transplant Proc 19 : 2245
13. Gershwin ME, Steinberg AD (1973) Loss of suppressor function as a cause of lymphoid malignancy. Lancet II: 1174
14. Gleichmann E, Gleichmann H, Schwartz RS, Weinblatt A, Armstrong MYK (1975) Immunologic induction of malignant lymphoma: identification of donor and host tumors in the graft-versus-host model. J Natl Cancer Inst 54: 107
15. Goldman M, Gérard C, Abramowicz D, Schandené L, Durez P, DePauw L, Kinnaert P, Vereerstraeten P, Velu T (1992) Induction of interleukin-6 and interleukin-10 by the OKT3 monoclonal antibody: possible relevance to post-transplant lymphoproliferative disorders. Clin Transplant 6 : 265
16. 40 virus tumorigenesis using irradiated homologous tumor antigen. Proc Soc Exp Biol 117 : 851
17. Gruber SA, Matas AJ (1994) Etiology and pathogenesis of tumors occurring after organ transplantation. Transplant Sci 4 : 87
18. Hanto DW, Birkenbach M, Frizzera G, Gajl-Peczalska KJ, Simmons RL, Schubach WH (1989) Confirmation of the heterogeneity of post-transplant Epstein-Barr virus-associated B cell proliferations by immunoglobulin gene rearrangement analyses. Transplantation 47 : 458
19. Hattori A, Perera MIR, Witkowski LA, Kunz HW, Gill TJ III, Shinozuka H (1986) Accelerated development of spontaneous thymic lymphomas in male AKR mice receiving cyclosporine. Transplantation 41 : 784
20. Hirsch MS, Proffitt MR, Black PH (1977) Autoimmunity, oncornaviruses, and lymphomagenesis. Contemp Top Immunobiol 6 : 209
21. Hornef MW, Bein G, Fricke L, Steinhoff J, Wagner H-J, Hinderer W, Sonneborn H-H, Kirchner H (1995) Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation 60 : 474
22. 1 donors cells. Transplant Proc 27 : 188
23. Kersey JH, Shapiro RS, Heinitz KJ, Greenberg JM, Blazar BR, McClain K, Filipovich AH (1987) Lymphoid malignancy in naturally occurring and post bone marrow transplantation immunodeficiency diseases. In: Good RA, Lindenlaub E (eds) The nature, cellular and biochemical basis and management of immunodeficiencies, vol 21. Shattaeur, Stuttgart, pp 289-294
24. Klein G, Klein E (1977) Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci USA 74 : 2121
25. Krueger G (1975) The significance of immunosuppression and antigenic stimulation in the development of malignant lymphomas. In Grundmann E, Gross R (eds) The ambivalence of cytostatic therapy, recent results in cancer research, vol 52. Springer, Berlin Heidelberg New York, pp 88-95
26. Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348 : 1357
27. Lukes RJ, Collins RD (1974) Immunologic characterization of human malignant lymphomas. Cancer 34 [Suppl 4]: 1488
28. Metcalf D (1963) Induction of reticular tumors in mice by repeated antigenic stimulation. Acta Unio Int Contra Cancrum 19 : 657
29. Montone KT, Litzky LA, Wurster A, Kaiser L, Bavaria J, Kotloff R, Palevsky H, Pietra GG, Tomaszewski JE (1996) Analysis of Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder after lung transplantation. Surgery 119 : 554
30. Nalesnik MA, Starzl TE (1997) On the crossroad between tolerance and post-transplant lymphoma. Curr Opin Organ Transplant 2 : 30
31. Nalesnik MA, Locker J, Jaffe R, Reyes J, Cooper M, Fung J, Starzl TE (1992) Experience with post-transplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplant 6 : 249
32. Nalesnik MA, Rao AS Furukawa H, Pham S, Zeevi A, Fung JJ, Klein G, Gritsch HA, Elder E, Whiteside TL, Starzl TE (1997) Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and-negative lymphoproliferative disorders in organ transplant recipients. Transplantation 63: 1200
33. Newell KA, Alonso EM, Whitington, PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR Jr (1996) Post-transplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosupression. Transplantation 62 : 370
34. Penn I (1989) Why do immunosuppressed patients develop cancer? In: Pimentel E (ed) CRC critical reviews in oncogenesis, vol 1., CRC, Boca Raton, pp 27-52
35. Penn I (1992) Immunosuppression - A contributory factor in lymphoma formation. Clin Transplant 6: 214
36. Penn I (1996) Cancers in cyclosporine-treated versus azathioprine-treated patients. Transplant Proc 28: 876
37. Penn I (1998) Neoplastic complications of organ transplantation. In: Ginns LC, Cosimi AB, Morris PJ (eds) Transplantation. Blackwell, Cambridge (in press)
38. Purtilo DT (1984) Defective immune surveillance in viral carcinogenesis. Lab Invest 51 : 373
39. Ras E, Michaeli J, Rosenmann E, Popovtzer M, Polliack A, Shouval D (1993) Excessive hepatitis-B surface antigen production after corticosteroids and the development of immunoblastic lymphoma. Leuk Lymphoma 10 : 241
40. Santana V, Rose NR (1983) Immunodysregulation and malignant lymphoproliferative disorders. Rec Adv Clin Immunol 2 : 51
41. Schwartz RS (1975) Another look at immunologic surveillance. N Engl J Medl 293 : 181
42. Selik RM, Starcher ET, Curran JW (1987) Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1 : 175-182
43. Sheil AGR, Disney APS, Mathew TG, Amiss N (1993) De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 25 : 1383
44. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1 : 583
45. Straus SE, Cohen JI, Tosato G, Mier J (1993) Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 118 : 45
46. Subar M, Neri A, Inghirami G, Knowles DM, Dalla-Favera R (1988) Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood 72 : 667
47. Swinnen L, Costanzo-Nordin M, Fisher S, O'Sullivan E, Johnson M, Heroux A, Dizikes G, Pifarre R, Fisher R (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 323 : 1723
48. Thomas L, Medawar PB (1959) Reactions to homologous tissue antigens in relation to hypersensitivity. In Lawrence HS (ed) Cellular and humoral aspects of the hypersensitive states. Hoeberg, New York, p 529
49. Van Gorp J, Doornewaard H, Verdonck LF, Klöpping C, Vos PF, Tweel JG van den (1994) Posttransplant T-cell lymphoma. Report of three cases and a review of the literature. Cancer 73 : 3064
50. Végh P, Baranyi L, Janossy T (1990) Induction of Transplantation tolerance and development of lymphomas in mice: lack of interdependence. Cell Immunol 129 : 56
51. Walford RL, Hildemann WH (1965) Life span and lymphoma-incidence of mice injected at birth with spleen cells across a weak histocompatibility locus. Am J Pathol 47 : 713
52. Wilkinson AH, Smith JL, Hunsicker LG, Tobacman J, Kapelanski DP, Johnson M, Wright FH, Behrendt DM, Corry RJ (1989) Increased frequency of post-transplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 47 : 293
53. Yuzawa K, Kondo I, Fukao K, Iwasaki Y, Hamaguchi H (1986) Mutagenicity of cyclosporine: induction of sister chroniatid exchange in human cells. Transplantation 42 : 61
54. Zanke BW, Rush DN, Jeffery JR, Israels LG (1989) HTLV-1 T cell lymphoma in a cyclosporine-treated renal transplant patient. Transplantation 48 : 695